NCT04401904View on ClinicalTrials.gov

SGLT2 Inhibition in Older Obese Adults With Pre-diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

September 14, 2022

Study Completion Date

September 14, 2022

Conditions
Aging
Interventions
DRUG

Dapagliflozin 10 mg

10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth

BEHAVIORAL

Nutritional counseling

10 participants randomized to receive 12 weeks of weekly counseling on nutrition

Trial Locations (2)

78207

Texas Diabetes Institute - University Health System, San Antonio

78229

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT04401904 - SGLT2 Inhibition in Older Obese Adults With Pre-diabetes | Biotech Hunter | Biotech Hunter